Ann: Becoming a substantial holder, page-8

I was thinking that maybe the dose would slag off a bit as doctors wait for the results from those studies before recommending SRX stuff.

But thinking about it now, you're right, it does make more sense that SRX existing business won't be affected by the new studies. One thing's for sure though, next year's sales will likely go through the roof.

Just re-read SRX presentation and their sales to date are only 2% of the current addressable market. It's just insane how the market could knock its share price down this low. But let's not complain too loudly.